ANNEXON INC. DL-,001

Annexon has added a second primary endpoint at 24 months to the ongoing phase‑3 ARCHER II trial of Vonaprument in dry age‑related macular degeneration; efficacy will now be assessed independently at 15 and 24 months. The double‑blind study has enrolled 659 participants (recruitment completed July 2025), with a dropout rate under 10% and compliance above 95%. An independent data monitoring committee will assess the 15‑month endpoint, with results expected in Q4 2026; study completion including 24‑month analyses is planned for Q3 2027. After month 24, patients may enter an open‑label extension with monthly Vonaprument treatment; primary endpoints measure confirmed losses of 15 letters in best‑corrected visual acuity, and safety and retinal secondary endpoints are also planned. » Plus sur de.investing.com

Annexon has appointed Dr. med. Mark S. Blumenkranz to its board of directors; at the same time Muneer Satter is leaving the board after more than 11 years. Blumenkranz is emeritus professor of ophthalmology at Stanford University, a co‑founder of several ophthalmology and life‑sciences companies, and brings broad experience in clinical and entrepreneurial development. Annexon is developing Vonaprument for the treatment of geographic atrophy and runs programs against neuroinflammatory diseases with a focus on the molecule C1q. » Plus sur de.investing.com

Annexon shares rose to a 52-week high of $7.10, gaining 64.15% over the past 12 months and 180.65% over six months. The biotech company has a market capitalization of $1.07 billion, more cash than debt and a current ratio of 4.42. Annexon completed a guaranteed capital raise of roughly $86.25 million before costs and filed for approval in the EU for Tanruprubart for Guillain–Barré syndrome. Analysts including Cantor Fitzgerald, Chardan and Clear Street rate the stock positively, while InvestingPro indicates a slight overvaluation at the current price. » Plus sur de.investing.com